CJC-1295 No DAC + Ipamorelin combines two research peptides that interact with separate receptor systems associated with growth-hormone-axis signaling.<\/p>\n
The material commonly referred to as CJC-1295 No DAC is Modified GRF (1-29), a GHRH analog investigated through GHRH-receptor signaling. Ipamorelin is a synthetic pentapeptide secretagogue investigated primarily through the ghrelin receptor, GHS-R1a.<\/p>\n
The blend provides a laboratory model for investigating interactions between these two receptor pathways.<\/p>\n
Specifications<\/b><\/strong><\/p>\n Product Classification:<\/b><\/strong>\u00a0Research Use Only (RUO) Research Applications<\/b><\/strong><\/p>\n The blend may be used in controlled laboratory models investigating:<\/p>\n Warning<\/b><\/strong><\/p>\n FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.<\/b><\/strong><\/p>\n This product is intended solely for qualified laboratory research and analytical applications.<\/p>\n Scientific Report<\/b><\/strong><\/p>\n Abstract<\/b><\/strong><\/p>\n Modified GRF (1-29) and Ipamorelin interact with separate receptor systems associated with growth-hormone-axis signaling.<\/p>\n Modified GRF (1-29) is investigated primarily through the GHRH receptor, while Ipamorelin is investigated as an agonist of GHS-R1a. Combining these research compounds provides a model for studying interactions between two mechanistically distinct signaling pathways.<\/p>\n Mechanistic Pathways<\/b><\/strong><\/p>\n Modified GRF (1-29) \/ GHRH Receptor<\/b><\/strong><\/p>\n Modified GRF (1-29) is a modified analog of the biologically active region of GHRH.<\/p>\n Research focus:<\/b><\/strong>\u00a0GHRH-receptor activation and associated downstream signaling.<\/p>\n Ipamorelin \/ GHS-R1a<\/b><\/strong><\/p>\n Ipamorelin is a synthetic pentapeptide investigated for agonist activity at GHS-R1a, also known as the ghrelin receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0GHS-R1a receptor activation and associated signaling.<\/p>\n Dual-Pathway Interaction<\/b><\/strong><\/p>\n Because the compounds interact with separate receptor systems, the blend can be investigated as a dual-pathway molecular model.<\/p>\n Research focus:<\/b><\/strong>\u00a0Interactions between GHRH-receptor and GHS-R1a-associated signaling.<\/p>\n Research Profile<\/b><\/strong><\/p>\n Compound 1:<\/b><\/strong>\u00a0Modified GRF (1-29) \/ CJC-1295 No DAC Compound 2:<\/b><\/strong>\u00a0Ipamorelin Blend Composition:<\/b><\/strong>\u00a05 mg \/ 5 mg Research Parameters<\/b><\/strong><\/p>\n Experimental conditions should be determined according to the laboratory model, assay methodology, and research endpoint. Appropriate controls and validated experimental protocols should be used.<\/p>\n No human or veterinary dosing, preparation, reconstitution, administration, or consumption instructions are provided.<\/p>\n Research Highlights<\/b><\/strong><\/p>\n Conclusion<\/b><\/strong><\/p>\n The 5 mg \/ 5 mg CJC-1295 No DAC + Ipamorelin blend provides two distinct molecular research tools within one preparation. Modified GRF (1-29) represents the GHRH-receptor component, while Ipamorelin represents the GHS-R1a component, allowing their respective signaling pathways and interactions to be investigated under controlled laboratory conditions.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" CJC-1295 No DAC + Ipamorelin combines two research peptides that interact with separate receptor systems associated with growth-hormone-axis signaling.<\/p>\n The material commonly referred to as CJC-1295 No DAC is Modified GRF (1-29), a GHRH analog investigated through GHRH-receptor signaling. Ipamorelin is a synthetic pentapeptide secretagogue investigated primarily through the ghrelin receptor, GHS-R1a.<\/p>\n The blend provides a laboratory model for investigating interactions between these two receptor pathways.<\/p>\n Specifications<\/b><\/strong><\/p>\n Product Classification:<\/b><\/strong>\u00a0Research Use Only (RUO) Research Applications<\/b><\/strong><\/p>\n The blend may be used in controlled laboratory models investigating:<\/p>\n Warning<\/b><\/strong><\/p>\n FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.<\/b><\/strong><\/p>\n This product is intended solely for qualified laboratory research and analytical applications.<\/p>\n Scientific Report<\/b><\/strong><\/p>\n Abstract<\/b><\/strong><\/p>\n Modified GRF (1-29) and Ipamorelin interact with separate receptor systems associated with growth-hormone-axis signaling.<\/p>\n Modified GRF (1-29) is investigated primarily through the GHRH receptor, while Ipamorelin is investigated as an agonist of GHS-R1a. Combining these research compounds provides a model for studying interactions between two mechanistically distinct signaling pathways.<\/p>\n Mechanistic Pathways<\/b><\/strong><\/p>\n Modified GRF (1-29) \/ GHRH Receptor<\/b><\/strong><\/p>\n Modified GRF (1-29) is a modified analog of the biologically active region of GHRH.<\/p>\n Research focus:<\/b><\/strong>\u00a0GHRH-receptor activation and associated downstream signaling.<\/p>\n Ipamorelin \/ GHS-R1a<\/b><\/strong><\/p>\n Ipamorelin is a synthetic pentapeptide investigated for agonist activity at GHS-R1a, also known as the ghrelin receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0GHS-R1a receptor activation and associated signaling.<\/p>\n Dual-Pathway Interaction<\/b><\/strong><\/p>\n Because the compounds interact with separate receptor systems, the blend can be investigated as a dual-pathway molecular model.<\/p>\n Research focus:<\/b><\/strong>\u00a0Interactions between GHRH-receptor and GHS-R1a-associated signaling.<\/p>\n Research Profile<\/b><\/strong><\/p>\n Compound 1:<\/b><\/strong>\u00a0Modified GRF (1-29) \/ CJC-1295 No DAC Compound 2:<\/b><\/strong>\u00a0Ipamorelin Blend Composition:<\/b><\/strong>\u00a05 mg \/ 5 mg Research Parameters<\/b><\/strong><\/p>\n Experimental conditions should be determined according to the laboratory model, assay methodology, and research endpoint. Appropriate controls and validated experimental protocols should be used.<\/p>\n No human or veterinary dosing, preparation, reconstitution, administration, or consumption instructions are provided.<\/p>\n Research Highlights<\/b><\/strong><\/p>\n Conclusion<\/b><\/strong><\/p>\n The 5 mg \/ 5 mg CJC-1295 No DAC + Ipamorelin blend provides two distinct molecular research tools within one preparation. Modified GRF (1-29) represents the GHRH-receptor component, while Ipamorelin represents the GHS-R1a component, allowing their respective signaling pathways and interactions to be investigated under controlled laboratory conditions.<\/p>\n <\/p>\n","protected":false},"featured_media":108,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[17],"product_tag":[],"class_list":["post-18","product","type-product","status-publish","has-post-thumbnail","product_cat-blend","first","instock","featured","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product\/18","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/comments?post=18"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/media\/108"}],"wp:attachment":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/media?parent=18"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_brand?post=18"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_cat?post=18"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_tag?post=18"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nTotal Content:<\/b><\/strong>\u00a010 mg total per vial
\nBlend Composition:<\/b><\/strong>\u00a05 mg CJC-1295 No DAC + 5 mg Ipamorelin
\nCompound 1:<\/b><\/strong>\u00a0Modified GRF (1-29) \/ CJC-1295 No DAC
\nCompound 2:<\/b><\/strong>\u00a0Ipamorelin
\nDAC:<\/b><\/strong>\u00a0None
\nForm:<\/b><\/strong>\u00a0Lyophilized peptide research blend
\nPackaging:<\/b><\/strong>\u00a0Research vial
\nPurity:<\/b><\/strong>\u00a0\u226599% (include only when supported by applicable batch documentation)<\/i><\/em>
\n<\/i><\/em>Intended Use:<\/b><\/strong>\u00a0Laboratory research and analytical purposes only<\/p>\n\n
\nPrimary Pathway:<\/b><\/strong>\u00a0GHRH receptor<\/p>\n
\nPrimary Pathway:<\/b><\/strong>\u00a0GHS-R1a \/ ghrelin receptor<\/p>\n
\nPrimary Research Area:<\/b><\/strong>\u00a0Dual-pathway signaling
\nResearch Setting:<\/b><\/strong>\u00a0Controlled laboratory and preclinical models<\/p>\n\n
\nTotal Content:<\/b><\/strong>\u00a010 mg total per vial
\nBlend Composition:<\/b><\/strong>\u00a05 mg CJC-1295 No DAC + 5 mg Ipamorelin
\nCompound 1:<\/b><\/strong>\u00a0Modified GRF (1-29) \/ CJC-1295 No DAC
\nCompound 2:<\/b><\/strong>\u00a0Ipamorelin
\nDAC:<\/b><\/strong>\u00a0None
\nForm:<\/b><\/strong>\u00a0Lyophilized peptide research blend
\nPackaging:<\/b><\/strong>\u00a0Research vial
\nPurity:<\/b><\/strong>\u00a0\u226599% (include only when supported by applicable batch documentation)<\/i><\/em>
\n<\/i><\/em>Intended Use:<\/b><\/strong>\u00a0Laboratory research and analytical purposes only<\/p>\n\n
\nPrimary Pathway:<\/b><\/strong>\u00a0GHRH receptor<\/p>\n
\nPrimary Pathway:<\/b><\/strong>\u00a0GHS-R1a \/ ghrelin receptor<\/p>\n
\nPrimary Research Area:<\/b><\/strong>\u00a0Dual-pathway signaling
\nResearch Setting:<\/b><\/strong>\u00a0Controlled laboratory and preclinical models<\/p>\n\n